Literature DB >> 14702160

Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacille Calmette-Guérin vaccine.

Rachel Pinto1, Bernadette M Saunders, Luis R Camacho, Warwick J Britton, Brigitte Gicquel, James A Triccas.   

Abstract

We demonstrate that Mycobacterium tuberculosis that is unable to export the complex lipid phthiocerol dimycocerosate has a decreased capacity to replicate in mice and affords sustained protective immunity against M. tuberculosis infection Protection was significantly better than that provided by the existing vaccine, Mycobacterium bovis bacille Calmette-Guérin (BCG), and this improved protective efficacy was maintained for at least 24 weeks after vaccination. Protection afforded by this attenuated strain coincided with a number of factors that were not associated with BCG vaccination: long-term persistence of the strain within the host, sustained and potent induction of antimycobacterial interferon-gamma-secreting cells equal to that induced by virulent M. tuberculosis, and elicitation of T cells recognizing dominant M. tuberculosis antigens absent from BCG. These results suggest that the BCG vaccine may be too attenuated to afford effective protective immunity against tuberculosis, and vaccine strains that can provide sustained delivery of mycobacterial antigens are promising antituberculosis vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14702160     DOI: 10.1086/380413

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Biochemical and structural characterization of an essential acyl coenzyme A carboxylase from Mycobacterium tuberculosis.

Authors:  Gabriela Gago; Daniel Kurth; Lautaro Diacovich; Shiou-Chuan Tsai; Hugo Gramajo
Journal:  J Bacteriol       Date:  2006-01       Impact factor: 3.490

2.  Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection.

Authors:  Teresa M Wozniak; Anthony A Ryan; James A Triccas; Warwick J Britton
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Transposon mutagenesis of Mb0100 at the ppe1-nrp locus in Mycobacterium bovis disrupts phthiocerol dimycocerosate (PDIM) and glycosylphenol-PDIM biosynthesis, producing an avirulent strain with vaccine properties at least equal to those of M. bovis BCG.

Authors:  Grant S Hotter; Barry J Wards; Pania Mouat; Gurdyal S Besra; Jessica Gomes; Monica Singh; Shalome Bassett; Pamela Kawakami; Paul R Wheeler; Geoffrey W de Lisle; Desmond M Collins
Journal:  J Bacteriol       Date:  2005-04       Impact factor: 3.490

4.  Immunogenicity and protective efficacy of the Mycobacterium tuberculosis fadD26 mutant.

Authors:  E Infante; L D Aguilar; B Gicquel; R Hernandez Pando
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

5.  Host cell-induced components of the sulfate assimilation pathway are major protective antigens of Mycobacterium tuberculosis.

Authors:  Rachel Pinto; Lisa Leotta; Erin R Shanahan; Nicholas P West; Thomas S Leyh; Warwick Britton; James A Triccas
Journal:  J Infect Dis       Date:  2012-12-07       Impact factor: 5.226

6.  A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.

Authors:  Michael V Tullius; Günter Harth; Sasa Maslesa-Galic; Barbara J Dillon; Marcus A Horwitz
Journal:  Infect Immun       Date:  2008-08-25       Impact factor: 3.441

7.  Potent antimycobacterial activity of the pyridoxal isonicotinoyl hydrazone analog 2-pyridylcarboxaldehyde isonicotinoyl hydrazone: a lipophilic transport vehicle for isonicotinic acid hydrazide.

Authors:  Samantha Ellis; Danuta S Kalinowski; Lisa Leotta; Michael L H Huang; Peter Jelfs; Vitali Sintchenko; Des R Richardson; James A Triccas
Journal:  Mol Pharmacol       Date:  2013-11-15       Impact factor: 4.436

8.  Assessment of live candidate vaccines for paratuberculosis in animal models and macrophages.

Authors:  Gabriella M Scandurra; Geoffrey W de Lisle; Sonia M Cavaignac; May Young; R Pamela Kawakami; Desmond M Collins
Journal:  Infect Immun       Date:  2009-12-28       Impact factor: 3.441

9.  Phthiocerol dimycocerosate transport is required for resisting interferon-gamma-independent immunity.

Authors:  Jeffrey P Murry; Amit K Pandey; Christopher M Sassetti; Eric J Rubin
Journal:  J Infect Dis       Date:  2009-09-01       Impact factor: 5.226

10.  Systems biology-based identification of Mycobacterium tuberculosis persistence genes in mouse lungs.

Authors:  Noton K Dutta; Nirmalya Bandyopadhyay; Balaji Veeramani; Gyanu Lamichhane; Petros C Karakousis; Joel S Bader
Journal:  MBio       Date:  2014-02-18       Impact factor: 7.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.